Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Iguratimod

A small-molecule disease-modifying antirheumatic drug (DMARD) derived from chromone: it curbs NF-κB activation, the production of inflammatory cytokines and antibody production by B cells. Approved in 2011 in China and in 2012 in Japan for rheumatoid arthritis. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It was discovered in Japan under the code T-614, but its first approval came in China, where it had been developed independently of the Japanese inventors.

IguratimodGo to the active ingredient →
IguratimodActive ingredientIguratimodCat. No. P-I022-001CAS 123663-49-0
Iguratimod-d5Isotopically labelledIguratimod-d5Cat. No. P-I022-002CAS 2816542-08-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.